David Evans Steps Down as Chairman of the Board for Horizon Discovery

23 Oct 2013

Cambridge, UK, 23 October 2013: Horizon Discovery (Horizon), a leading provider of research tools to support the development of personalized medicines, today announced Mr. David Evans has stepped down as Chairman of the Board. Dr. Ian Gilham, who was recently appointed as a non-executive director for Horizon Discovery, will act as interim Chairman. Horizon is actively seeking a high profile non-executive with international standing to act as Chairman, who will work closely with the Board of Directors and CEO.

David has been Non-Executive Chairman of the Board of Directors of Horizon Discovery since 2009. During this time he oversaw the company’s growth from 15 to 80 FTE’s, a compound annual revenue growth rate of >120% and a 6 times increase in valuation. An entrepreneurial accountant who has been involved in various organizations in the diagnostics and life sciences fields including BBI, IDS and DxS, David has a strong track record in both executive and non-executive roles.

Dr. Darrin M Disley, CEO of Horizon, said: “On behalf of Horizon’s Management Team and Board of Directors I would like to thank David for his integrity, hard work and unwavering support. He remains a significant investor, trusted advisor and friend of the company and we wish him well. As interim Chairman Ian’s commercial and investor relations experience will be greatly valued, as Horizon continues to develop as a world-leading translational genomics organization.”

David Evans commented: “It has been a pleasure to work with Horizon, one of the leading lights of the British biotech industry. The company has a strong future ahead, and I look forward to seeing its growth over the coming years.”

Ian Gilham was appointed Non-Executive Director of Horizon Discovery in August 2013. He is also non-executive chairman of Multiplicom NV and Biosurfit SA, and Director of Stowheath Ltd. Ian has previously been CEO of Axis-Shield plc and Vice President, Pharmacogenetics and Diagnostics at GSK, as well as holding various positions within Abbott Laboratories.

Horizon’s mission is to provide its customers with cutting-edge biological tools and services that will accelerate the pace of development of ‘personalized’ medicines.